Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Harris

Family Medicine Greenville, SC Medical Doctor

NPI 1215134978 CMS profile 9369

142 Milestone Way, Greenville, SC 29615

Open in the dashboard

General payments

$4,224

184 records reported · program years 2019–2025

Research payments

$96,482

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,396,456 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Jeffrey Harris of Greenville, SC is reported in the CMS Open Payments database as having received $4,224 across 184 general payments and $96,482 in research payments paid to them. Separately, studies naming them as principal investigator received $3,396,456 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $327 16
2024 General $614 31
2023 General $804 58
2022 General $447 24
2021 General $258 13
2021 Research $96,482 4
2020 General $198 14
2019 General $1,575 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Harris
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Jeffrey Harris were reported at $327. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Jeffrey Harris Family Medicine median Middle half National median
2019 $1,575 $150 $41–$543 $163
2020 $198 $120 $32–$415 $114
2021 $258 $137 $35–$551 $132
2022 $447 $137 $37–$512 $149
2023 $804 $149 $42–$545 $160
2024 $614 $156 $44–$560 $164
2025 $327 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Indivior Inc. $1,191 11 payments
  2. Supernus Pharmaceuticals, Inc. $780 56 payments
  3. Tris Pharma Inc $467 29 payments
  4. Ironshore Pharmaceuticals Inc. $467 27 payments
  5. Corium, Inc. $307 16 payments
  6. Neos Therapeutics, LP $237 12 payments
  7. Abbott Laboratories $180 1 payment
  8. AbbVie, Inc. $130 6 payments
  9. Noven Therapeutics, LLC $90 4 payments
  10. Adlon Therapeutics L.P. $76 5 payments
  11. Other $299 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,223 182 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,000 1 payment
  3. Education $1 1 payment
Products named General payments · program years 2019–2025
  1. SUBLOCADE $1,131 8 payments
  2. QELBREE Psychology $405 38 payments
  3. Qelbree Viloxazine Hydrochloride $375 18 payments
  4. Azstarys $307 16 payments
  5. Dyanavel XR $285 17 payments
  6. JORNAY PM Central Nervous Stimulant ADHD $281 17 payments
  7. Proclaim Family of SCS IPGs $180 1 payment
  8. Adzenys XR-ODT $177 9 payments
  9. JORNAY PM Central Nervous System Stimulant $150 8 payments
  10. Xelstrym $90 4 payments
  11. Other $973 55 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Becton, Dickinson and Company $96,482 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

15

Median for Family Practice: 1,826

Drug cost

$2,039

Median for Family Practice: $120,094

Branded share of claims

100%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 15 $2,039

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qelbree
  • Supernus Pharmaceuticals, Inc. $257
$257 — —
Dyanavel XR
  • Tris Pharma Inc $86
$86 — —
Xelstrym
  • Noven Therapeutics, LLC $66
$66 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $52
$52 — —
Azstarys
  • Corium, Inc. $46
$46 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

188 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record